Weng S, Spiro R G
Department of Biological Chemistry, Harvard Medical School, Boston, MA 02215, USA.
Glycobiology. 1996 Dec;6(8):861-8. doi: 10.1093/glycob/6.8.861.
Since it has become apparent that the early processing of the N-linked oligosaccharides of glycoproteins can proceed by several routes, we undertook to determine whether the isomeric nature of Man8GlcNAc2, which is the first intermediate with the potential for structural diversity, can provide information relating to the pathways utilized in various intact cultured cells as well as in the total membrane fraction derived from these cells (BW5147.3, HepG2, HL60, F-9, and MDCK). With the use of kifunensine (KIF) to block processing by Golgi mannosidase I, it could be shown that a substantial amount of Man8GlcNAc2 components in which the terminal mannose is missing in the alpha 1,3-linked and alpha 1,6-linked chain (isomers A and C, respectively) are produced, although in the absence of the inhibitor only the B-isomer, in which the mannose of the middle chain has been excised, was apparent. Our findings in vivo and in vitro suggest that the distinctive Man8GlcNAc2 product of endomannosidase (isomer A) and of ER mannosidase II (isomer C) are not evident in the absence of KIF, since they are rapidly degraded by Golgi mannosidase I, which is located in an intracellular compartment distal to the other two enzymes and itself exclusively generates the Man8GlcNAc2 isomer B. Investigations carried out in HepG2 cells indicated that glycoproteins with N-linked oligosaccharides whose processing has been blocked by KIF at the Man8GlcNac2 isomer A and C stage can nevertheless be effectively secreted. The observation that isomer A of Man8GlcNAc2 is a specific product of endomannosidase action made it possible to demonstrate the action of this enzyme in vivo without employing a glucosidase blockade and to show that a substantial amount of the deglucosylation of N-linked oligosaccharides is carried out by this enzyme.
由于糖蛋白的N-连接寡糖的早期加工可以通过多种途径进行这一点已变得很明显,我们着手确定Man8GlcNAc2的异构体性质是否能提供有关各种完整培养细胞以及源自这些细胞(BW5147.3、HepG2、HL60、F-9和MDCK)的总膜组分中所利用途径的信息,Man8GlcNAc2是具有结构多样性潜力的首个中间体。通过使用基弗那辛(KIF)来阻断高尔基体甘露糖苷酶I的加工,可以表明产生了大量的Man8GlcNAc2组分,其中α1,3-连接链和α1,6-连接链(分别为异构体A和C)中的末端甘露糖缺失,尽管在没有抑制剂的情况下,只有中间链的甘露糖已被切除的B-异构体是明显的。我们在体内和体外的研究表明,在没有KIF的情况下,内切甘露糖苷酶(异构体A)和内质网甘露糖苷酶II(异构体C)的独特Man8GlcNAc2产物并不明显,因为它们会被高尔基体甘露糖苷酶I迅速降解,高尔基体甘露糖苷酶I位于比其他两种酶更远的细胞内区室中,并且其自身仅产生Man8GlcNAc2异构体B。在HepG2细胞中进行的研究表明,其N-连接寡糖加工在Man8GlcNac2异构体A和C阶段被KIF阻断的糖蛋白仍然可以有效地分泌。Man8GlcNAc2异构体A是内切甘露糖苷酶作用的特异性产物这一观察结果使得在不采用葡糖苷酶阻断的情况下在体内证明该酶的作用成为可能,并表明N-连接寡糖的大量去糖基化是由该酶进行的。